New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years. However, many patients require ...

Please provide your email address to receive an email when new articles are posted on . A literature search identified 70 eyes with retinal vasculitis or vascular occlusion following brolucizumab for ...

Retinal artery occlusion was associated with a 1.56-fold increased risk for acute coronary syndrome (relative risk [RR], 1.56; 95% CI, 1.22-1.99) and a twofold increased risk for all-cause mortality ...

COVID-19 infection may be boosting the numbers of a rare ocular condition in which vision is threatened when veins in the retina are blocked, eye specialists in Southern California report. Risk of ...

Patients with retinal artery occlusions (RAOs) had subsequent increased risks of death, stroke, and myocardial infarction (MI) over both the short and long term compared with matched controls with ...

Please provide your email address to receive an email when new articles are posted on . Women who filled a prescription for female hormone therapy did not have an increased risk for retinal vein ...

– RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema – – Approval is based on two Phase III studies demonstrating ...

A real-world safety study found that patients treated with brolucizumab had low occurrences of intraocular inflammation, retinal vascular occlusion, and retinal vasculitis. A study published in ...

This interview is a translation of a video blog posted on Medscape France. It has been edited for clarity. Philippe Gabriel Steg, MD: Hello. Today, I would like to address a subject that many ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...